Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
LAG-3抑制剂ieramilimab (LAG525)联合或不联合抗PD-1 spartalizumab (PDR001)治疗晚期恶性肿瘤患者的I/II期研究
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2021-003776
Schöffski, Patrick; Tan, Daniel S W; Martín, Miguel; Ochoa-de-Olza, María; Sarantopoulos, John; Carvajal, Richard D; Kyi, Chrisann; Esaki, Taito; Prawira, Amy; Akerley, Wallace; De Braud, Filippo; Hui, Rina; Zhang, Tian; Soo, Ross A; Maur, Michela; Weickhardt, Andrew; Krauss, Jürgen; Deschler-Baier, Barbara; Lau, Allen; Samant, Tanay S; Longmire, Tyler; Chowdhury, Niladri Roy; Sabatos-Peyton, Catherine A; Patel, Nidhi; Ramesh, Radha; Hu, Tiancen; Carion, Ana; Gusenleitner, Daniel; Yerramilli-Rao, Padmaja; Askoxylakis, Vasileios; Kwak, Eunice L; Hong, David S